EP0871659A4 - Fusion proteins comprising cell cycle regulatory proteins - Google Patents

Fusion proteins comprising cell cycle regulatory proteins

Info

Publication number
EP0871659A4
EP0871659A4 EP97901350A EP97901350A EP0871659A4 EP 0871659 A4 EP0871659 A4 EP 0871659A4 EP 97901350 A EP97901350 A EP 97901350A EP 97901350 A EP97901350 A EP 97901350A EP 0871659 A4 EP0871659 A4 EP 0871659A4
Authority
EP
European Patent Office
Prior art keywords
fusion proteins
purification
affinity chromatography
proteins
facilitate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97901350A
Other languages
German (de)
French (fr)
Other versions
EP0871659A1 (en
Inventor
Steven Kovacevic
Keith A Otto
Ramachandra N Rao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of EP0871659A1 publication Critical patent/EP0871659A1/en
Publication of EP0871659A4 publication Critical patent/EP0871659A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Abstract

The present invention provides novel fusion proteins comprising cyclins and CDKs. A preferred embodiment of the invention provides fusion proteins comprising human cyclin D1 and human CDK4. The fusion proteins of the invention optionally contain modifications, which facilitate their purification. Addition of histidine residues to selected constructs allows purification via immobilized metal affinity chromatography. Antigenic determinants allowing monoclonal antibody-based affinity chromatography purification are provided in selected embodiments of the invention. Protease cleavage sites are incorporated in selected constructs to allow cleavage of the regions incorporated in the cyclin-CDK fusion proteins for purification. Additional modifications which facilitate purification include strepavadin binding domains and antigenic determinants for antibody affinity chromatography.
EP97901350A 1996-01-05 1997-01-03 Fusion proteins comprising cell cycle regulatory proteins Withdrawn EP0871659A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US962996P 1996-01-05 1996-01-05
US9629P 1996-01-05
PCT/US1997/000140 WO1997025345A1 (en) 1996-01-05 1997-01-03 Fusion proteins comprising cell cycle regulatory proteins

Publications (2)

Publication Number Publication Date
EP0871659A1 EP0871659A1 (en) 1998-10-21
EP0871659A4 true EP0871659A4 (en) 2000-04-26

Family

ID=21738815

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97901350A Withdrawn EP0871659A4 (en) 1996-01-05 1997-01-03 Fusion proteins comprising cell cycle regulatory proteins

Country Status (4)

Country Link
EP (1) EP0871659A4 (en)
AU (1) AU1526897A (en)
CA (1) CA2241849A1 (en)
WO (1) WO1997025345A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5986055A (en) * 1997-11-13 1999-11-16 Curagen Corporation CDK2 interactions
US6432668B1 (en) 1997-12-30 2002-08-13 Chiron Corporation Polynucleotides encoding human cyclin-dependent kinase (hPFTAIRE)
KR20000019889A (en) * 1998-09-16 2000-04-15 성재갑 Preparation method for cdk4/p16 complex using insect cells
ATE519840T1 (en) * 1998-12-16 2011-08-15 Novartis Vaccines & Diagnostic HUMAN CYCLIN DEPENDENT KINASE (HPNQALRE)
PT1232264E (en) 1999-11-18 2009-11-26 Novartis Vaccines & Diagnostic Human fgf-21 gene and gene expression products
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
AU2001249125A1 (en) 2000-03-08 2001-09-17 Chiron Corporation Human fgf-23 gene and gene expression products
DE10113776B4 (en) * 2001-03-21 2012-08-09 "Iba Gmbh" Isolated streptavidin-binding, competitively elutable peptide, this comprehensive fusion peptide, nucleic acid coding therefor, expression vector, methods for producing a recombinant fusion protein and methods for detecting and / or obtaining the fusion protein
WO2014037460A2 (en) * 2012-09-05 2014-03-13 Universite Libre De Bruxelles Immobilised cyclin-dependent kinase 4 fusion proteins and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196320A (en) * 1989-09-20 1993-03-23 Abbott Biotech, Inc. Method of producing engineered binding proteins

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL NUCLEOTIDE SEQU 1 January 1900 (1900-01-01), XP002131313, Database accession no. P24385 *
DATABASE EMBL NUCLEOTIDE SEQU 1 January 1900 (1900-01-01), XP002131314, Database accession no. P11802 *
RAO, R.N. ET AL.: "Conditional transformation of rat embryo fibroblast cells by a cyclin D1-cdk4 fusion gene", ONCOGENE, vol. 18, no. 46, November 1999 (1999-11-01), pages 6343 - 6356, XP000870164 *
See also references of WO9725345A1 *
TAM, S.W. ET AL.: "Differential expression and regulation of Cyclin D1 protein in normal and tumor human cells: association with Cdk4 is required for Cyclin D1 function in G1 progression", ONCOGENE, vol. 9, no. 9, September 1994 (1994-09-01), pages 2663 - 2674, XP000864419 *

Also Published As

Publication number Publication date
AU1526897A (en) 1997-08-01
CA2241849A1 (en) 1997-07-17
EP0871659A1 (en) 1998-10-21
WO1997025345A1 (en) 1997-07-17

Similar Documents

Publication Publication Date Title
EP1712623A3 (en) Selection of proteins using RNA-protein fusions
AU5958996A (en) Monoclonal antibodies for human mesenchymal stem cells
EP1106183A3 (en) Antibodies to erbB2 and their therapeutic uses
NZ310847A (en) High affinity human monoclonal antibodies specific for rsv fusion protein
WO2000005265A3 (en) Anti-crr2 antibodies and methods of use therefor
HK1020990A1 (en) Antibodies to the ed-b domain of fibronectin, their construction and uses
EP0724456A4 (en) Antibodies to cd40
WO2000078344A8 (en) Prion protein peptides and uses thereof
PL336306A1 (en) Proteinous fusions of tgf-beta ii type receptor with a constant immunoglobulin area
WO2003059935A3 (en) Methods for purifying protein
DE69531679D1 (en) FOR E-SELECTIN AND P-SELECTIN-SPECIFIC CROSS-REACTIVE MONOCLONAL ANTIBODIES
AU4643596A (en) Chimeric antibodies comprising antigen binding sites and b and t cell epitopes
IL152886A0 (en) B-7 related nucleic acids and polypeptides and pharmaceutical compositions containing the same
EP0930366A3 (en) Binding domains in delta proteins
NZ512083A (en) Methods of increasing lean tissue mass using OB protein compositions
EP0871659A4 (en) Fusion proteins comprising cell cycle regulatory proteins
WO2001068708A3 (en) Human and humanized fap-alpha-specific antibodies
EP1433792A8 (en) Human receptor proteins, related reagents and methods
EP0626450A3 (en) Ubiquitin conjugating enzyme (E2) fusion proteins.
DK1167389T3 (en) Antibodies to the SEMP1 protein, method of preparation thereof, and use thereof
WO2001036467A3 (en) Mammalian receptor proteins; related reagents and methods
BR9709900A (en) Protein binding proteins of prions and their uses.
WO1999046379A3 (en) Human receptor proteins; related reagents and methods
AU1971295A (en) Humanized monoclonal antibodies against human interleukin-4
NZ333408A (en) Methods for determining the presence of brain protein s-100

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980703

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20000309

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000518